



ASX release

19 February 2009

AtCor reports maiden profit for first half

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced a maiden profit after tax of \$180,477 for H1 2009 (H1 2008: \$1,678,798 loss). Sales were \$5.4 million, a 76% increase over H1 2008 and a record for the company. On a constant currency basis, sales increased by 64% over H1 2008.

The company's positive earnings resulted from its strong sales performance, continued focus on expense management and the depreciation of the Australian dollar against AtCor's major export currencies. Expenses were up by 12% compared with H1 2008, with approximately 40% of this increase attributable to the Australian dollar devaluation and 30% attributable to higher sales commissions and bonuses related to company performance. Gross margin for the half was in line with H1 2008 at 83%.

Operating cash outflow fell by over 50%. With increasing sales, strong trade receivables and a continued reduction in cash outflow expected, AtCor does not anticipate a need to raise funds for operating purposes in the foreseeable future.

Outlook

AtCor chief executive officer Duncan Ross said, 'We are delighted by these strong results, which reflect growing appreciation of the importance of central blood pressures and of the key role that SphygmoCor can play in patient care. We are off to a good start for the second half and maintain our guidance of a 55% sales increase to over \$10 million for the full year. As the vast majority of our sales are exports whilst non-sales related expenses are incurred in Australian dollars, AtCor will continue to benefit from the discount of the AUD against the major currencies.

'We are focused on leveraging our expense investment to optimize sales and margin as we drive the business towards our goal of continuing positive cash flow and earnings.'

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,800 SphygmoCor[®] systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au